Arrowhead Pharmaceuticals reports FY2026 loss, REDEMPLO growth and plans SHTG launch
Arrowhead Pharmaceuticals announced FY2026 results, posting a net loss of $724.2 million on revenue of $450.8 million. The company highlighted that REDEMPLO generated 950 new‑to‑brand prescriptions, over 860 prescribers and coverage for more than 160 million U.S. lives. Management said it is preparing a U.S. launch of REDEMPLO for severe hypertriglyceridemia (SHTG) in Q2 2027 and projects $3‑$4 billion of annual sales if approved. A $215 million one‑time priority‑review‑voucher expense and the loss of prior‑year collaboration revenue drove the earnings miss.
Why it matters
The loss and revenue decline reflect a sharp earnings miss, which could weigh on ARWR’s share price in the short term (the company’s earnings release notes the miss). Management’s projection of a $3‑$4 billion annual U.S. sales opportunity for REDEMPLO in SHTG, if realized, could materially improve future earnings and cash flow.
Key facts
- 1Net loss of $724.2 million, or $5.11 per share, for FY2026. finance.biggo.com
- 2Revenue of $450.8 million for FY2026. finance.biggo.com
- 3New‑to‑brand REDEMPLO prescriptions reached 950 as of September 30 2026, up 63% quarter‑over‑quarter. ir.arrowheadpharma.com
- 4Prescriber base grew to over 860 unique prescribers by early November 2026. ir.arrowheadpharma.com
- 5More than 160 million U.S. lives are covered on payer formularies for REDEMPLO. ir.arrowheadpharma.com
- 6Company is targeting a U.S. launch of REDEMPLO for severe hypertriglyceridemia in Q2 2027, with an sNDA submitted on November 2 2026. ir.arrowheadpharma.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.